	US 12,064,399 B2
	Use of cannabinoids in the treatment of epilepsy
Geoffrey Guy, Cambridge (GB); Stephen Wright, Altrincham (GB); and Orrin Devinsky, New York, NY (US)
Assigned to Jazz Pharmaceuticals Research UK Limited, Kent (GB)
Filed by Jazz Pharmaceuticals Research UK Limited, Kent (GB)
Filed on May 13, 2022, as Appl. No. 17/744,224.
Application 17/744,224 is a continuation of application No. 16/893,018, filed on Jun. 4, 2020, granted, now 11,357,741.
Application 16/893,018 is a continuation of application No. 15/183,947, filed on Jun. 16, 2016, granted, now 10,709,671, issued on Jul. 14, 2020.
Claims priority of application No. 1510664 (GB), filed on Jun. 17, 2015.
Prior Publication US 2022/0387348 A1, Dec. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61K 31/352 (2006.01); A61K 31/5513 (2006.01); A61K 36/185 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01); A61P 25/08 (2006.01)

CPC A61K 31/05 (2013.01) [A61K 31/352 (2013.01); A61K 31/5513 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01); A61P 25/08 (2018.01)]

28 Claims

1. A method of treating focal seizures in Lennox-Gastaut Syndrome or Tuberous Sclerosis Complex, comprising administering to a subject in need thereof a drug product comprising a cannabidiol (CBD) drug substance, wherein the CBD drug substance has a purity of at least 98% (w/w), wherein the CBD is administered at a dose ranging from about 5 mg/kg/day to about 25 mg/kg/day.